PortViewPortView
Qiagen N.V. logo

Qiagen N.V. (QGEN) Stock Analysis

NYSEHealthcareMedical - Diagnostics & Research

$44.16+1.76%
1-year price historyRange $32.63 – $55.66
52-week range$44.16
$32.53$57.82

What Qiagen N.V. does

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Key metrics

Market cap
$9.11B
P/E (TTM)
18.25
EPS (TTM)
$2.42
Beta
0.62
Dividend yield
5.98%
Revenue / share
$10.18
50-day avg
$41.56
200-day avg
$42.74
52-week high
$57.82
52-week low
$32.53
CEO
Thierry L. Bernard

ETFs linked to QGEN

Broad-market and Healthcare sector ETFs an investor holding Qiagen N.V. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how QGEN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze QGEN in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Qiagen N.V.?
Qiagen N.V. trades under the ticker QGEN on NYSE.
Which exchange is QGEN listed on?
QGEN is listed on NYSE.
What sector does Qiagen N.V. operate in?
Qiagen N.V. is classified in the Healthcare sector (Medical - Diagnostics & Research industry).
How can PortView help analyze QGEN in a portfolio?
PortView shows QGEN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.